Project Grant R01DK141150
Award Date
7/15/24
Completion Date
6/30/28
Dollars Obligated
$603K
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
New York, NY 10032, USA
Similar Awards
This $1,207,770 Cooperative Agreement award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research, supports research to investigate genetic abnormalities and autoimmune processes underlying type 1 diabetes (T1D) pathogenesis. The project will utilize a novel "personalized immune" (PI) mouse model to recreate the diverse human T1D-associated genetic profiles and assess the impact...
This federal Cooperative Agreement award of $1,108,154 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to develop a stem cell-based multi-cellular platform that integrates diverse types of immune cells with stem cell-derived islets. The primary goals are to: Optimize the differentiation of islets and macrophages from the same cell line, 2) Identify the appropriate...
This Cooperative Agreement award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) provides $1,201,988.00 to Yale University to develop advanced pancreatic-immune organoid models to study type 1 diabetes (T1D) progression and therapeutic responses. The key objectives are to: 1) Characterize and analyze pancreatic organoids derived from induced pluripotent stem cells (iPSCs) of 10 T1D patients and...
This Cooperative Agreement award of $1,232,846 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to study the mechanisms of beta cell death in type 1 diabetes. The primary goals are to develop a microfluidic platform with syngeneic human cell types, including induced pluripotent stem cell-derived pancreatic endocrine cells, blood vessels, macrophages,...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $324,998 to support the development of advanced stem cell-derived pancreatic islet cell technologies for type 1 diabetes treatment. The key products and services to be delivered include: Assessing the impact of genetically modifying stem cell-derived islet cells to be more resilient to...
This Project Grant award of $568,075 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research supports research to determine the role of the NR4A1 transcription factor in pathways that can expand functional beta cell mass as a potential treatment for type 1 and type 2 diabetes. The research aims to elucidate how NR4A1 interacts with GLP-1 receptor signaling and DYRK1A inhibition to enhance...
This $148,568 Project Grant was awarded on January 9, 2025 by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports research conducted by The Leland Stanford Junior University to: 1) Optimize a low-intensity conditioning protocol to generate stable mixed hematopoietic chimerism and induce donor-specific tolerance for allogeneic islet transplantation, and 2)...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $561,893 to Weill Medical College of Cornell University to systematically evaluate the molecular cascade involving type 2 diabetes (T2D) effector genes, the transcription factors RFX3 and RFX6, and T2D-associated genetic variants. The research aims to establish human pluripotent...
This Project Grant award, totaling $1,331,148, was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports research at Yale University to investigate the mechanisms by which pancreatic alpha cells compensate for deficiencies in beta cell mass in type 2 diabetes. The key objectives are to: (1) determine the signaling mechanisms underlying beta cell...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $601,340 to Transchromix LLC to develop a novel therapeutic intervention for early-stage type 1 diabetes (T1D). The research aims to target a translational regulatory mechanism involving the G9A histone methyltransferase, which was found to specifically suppress the pathogenicity of...